Westside Investment Management Inc. grew its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 396.7% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,725 shares of the biopharmaceutical company’s stock after purchasing an additional 2,975 shares during the period. Westside Investment Management Inc.’s holdings in Alexion Pharmaceuticals were worth $461,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently bought and sold shares of ALXN. BlackRock Inc. grew its position in shares of Alexion Pharmaceuticals by 2,689.8% in the first quarter. BlackRock Inc. now owns 18,628,080 shares of the biopharmaceutical company’s stock valued at $2,258,467,000 after purchasing an additional 17,960,356 shares in the last quarter. Third Point LLC purchased a new stake in shares of Alexion Pharmaceuticals in the second quarter valued at approximately $152,088,000. Bank of Montreal Can grew its position in shares of Alexion Pharmaceuticals by 628.8% in the second quarter. Bank of Montreal Can now owns 1,423,318 shares of the biopharmaceutical company’s stock valued at $173,174,000 after purchasing an additional 1,228,025 shares in the last quarter. Janus Henderson Group PLC grew its position in shares of Alexion Pharmaceuticals by 1,697.6% in the second quarter. Janus Henderson Group PLC now owns 1,145,918 shares of the biopharmaceutical company’s stock valued at $139,424,000 after purchasing an additional 1,082,171 shares in the last quarter. Finally, TIAA CREF Investment Management LLC grew its position in shares of Alexion Pharmaceuticals by 42.2% in the second quarter. TIAA CREF Investment Management LLC now owns 3,219,961 shares of the biopharmaceutical company’s stock valued at $391,773,000 after purchasing an additional 955,578 shares in the last quarter. Institutional investors and hedge funds own 94.25% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded down 1.73% during mid-day trading on Friday, hitting $141.30. The stock had a trading volume of 1,104,777 shares. The stock has a market cap of $31.54 billion, a P/E ratio of 61.27 and a beta of 1.39. Alexion Pharmaceuticals, Inc. has a 12-month low of $96.18 and a 12-month high of $149.34. The company’s 50 day moving average price is $141.26 and its 200 day moving average price is $126.29.

Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its quarterly earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping analysts’ consensus estimates of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The firm had revenue of $912.00 million during the quarter, compared to analysts’ expectations of $846.15 million. During the same period in the prior year, the company earned $1.13 EPS. The firm’s revenue was up 21.1% on a year-over-year basis. Equities research analysts predict that Alexion Pharmaceuticals, Inc. will post $5.60 EPS for the current fiscal year.

In related news, Director Ann M. Veneman sold 700 shares of the company’s stock in a transaction on Monday, July 31st. The shares were sold at an average price of $137.74, for a total transaction of $96,418.00. Following the completion of the sale, the director now directly owns 6,315 shares of the company’s stock, valued at approximately $869,828.10. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Julie O’neill sold 11,160 shares of the company’s stock in a transaction on Monday, August 28th. The stock was sold at an average price of $140.00, for a total transaction of $1,562,400.00. Following the sale, the executive vice president now directly owns 26,704 shares of the company’s stock, valued at $3,738,560. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 17,190 shares of company stock valued at $2,433,669. 4.35% of the stock is owned by corporate insiders.

A number of research firms have recently issued reports on ALXN. Royal Bank Of Canada began coverage on Alexion Pharmaceuticals in a research report on Thursday, September 14th. They issued an “outperform” rating and a $161.00 price target for the company. J P Morgan Chase & Co upgraded Alexion Pharmaceuticals from a “neutral” rating to an “overweight” rating and upped their price target for the company from $163.00 to $175.00 in a research report on Tuesday, September 5th. BMO Capital Markets restated an “outperform” rating and issued a $173.00 price target (up from $168.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Deutsche Bank AG restated a “buy” rating and issued a $158.00 price target (up from $153.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Finally, SunTrust Banks, Inc. restated a “buy” rating and issued a $180.00 price target (up from $170.00) on shares of Alexion Pharmaceuticals in a research report on Wednesday, September 13th. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and two have given a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $154.56.

TRADEMARK VIOLATION NOTICE: This piece was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.thecerbatgem.com/2017/10/07/westside-investment-management-inc-has-461000-stake-in-alexion-pharmaceuticals-inc-alxn.html.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Stock Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.